Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study

Fig. 2

Elevation of serum sAXL in biomarker-positive DAT subjects. Differences of sAXL serum levels between subject groups based on screening diagnosis or CSF biomarker profile. Violin plots with median and interquartile range. Groups colored red were elevated against groups colored blue. Gray color indicates indifferent groups. Further statistical details are described in Additional file 1: Tables S2-S4. Serum sAXL levels were elevated in DAT versus SCD or HC subjects (A), as well as in either p-tau-based A+T+ subjects (B) or t-tau-based A+N+ subjects (C) against A−T− or A−N− subjects, respectively. There was no significant elevation in either MCI subjects or those with only amyloid or tau isoform-positive CSF biomarker profile

Back to article page